Skip to main
GOSS
GOSS logo

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Gossamer Bio Inc. has garnered positive sentiment among key opinion leaders (KOLs) in pulmonary arterial hypertension (PAH), with expectations for its product PROSERA to achieve a significant treatment effect, potentially in the range of 25 to 30 meters in the six-minute walk distance (6MWD). Despite some imperfections in the phase 2 TORREY study results, the data demonstrated consistent benefits across multiple endpoints, including pulmonary vascular resistance (PVR) reduction and pro-BNP reduction, alongside a favorable safety profile and promising durability. Increased investor interest has been noted following bullish commentary from KOLs during a recent panel discussion, indicating a rising confidence in Gossamer Bio's pipeline and market potential.

Bears say

Gossamer Bio Inc is facing a negative outlook due to the market's ongoing mispricing of seralutinib's success probabilities, which raises concerns about the validity of investor enthusiasm following a recent stock increase. The company’s clinical-stage pipeline, while focusing on critical disease areas, may not adequately offset the risks associated with the uncertainty surrounding seralutinib's chances of regulatory approval or market acceptance. Furthermore, Gossamer Bio's reliance on a few key products in its pipeline highlights potential vulnerabilities, as any setbacks in clinical trial results could significantly impact overall financial stability.

GOSS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Strong Buy based on their latest research and market trends.

According to 5 analysts, GOSS has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.